Compare SURG & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | LTRN |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 22.2M |
| IPO Year | N/A | 2020 |
| Metric | SURG | LTRN |
|---|---|---|
| Price | $0.51 | $3.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 578.5K | 282.8K |
| Earning Date | 04-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $136.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $1.11 |
| 52 Week High | $3.45 | $5.74 |
| Indicator | SURG | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 70.09 |
| Support Level | $0.48 | $3.04 |
| Resistance Level | $0.94 | $3.79 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 19.94 | 88.72 |
Surgepays Inc is a wireless and point of sale technology company focused on serving underserved and value-conscious consumers through a combination of retail distribution and digital acquisition channels. It provides mobile connectivity, financial technology services, and transaction processing solutions through an integrated platform that combines wireless services with point of sale software and retail distribution. It enables in-store and online activation of wireless services, prepaid top-ups, and financial transactions, allowing consumers to access essential services in both local and digital environments. Its segments are wireless services or MVNO Telecommunications, platform services or MVNE Enablement Platform (HERO), and wholesale enablement or Comprehensive Platform Services.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.